TRANSPHORM, INC. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2ac1ceb7-6222-4294-a2bc-207fd402c434/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-28.8M | 2022-04-01 – 2023-03-31 | evidence 0001715768-23-000047 |
| FY 2021 | $-9.9M | 2021-04-01 – 2022-03-31 | evidence 0001715768-22-000028 |
| FY 2020 | $-13.4M | 2020-01-01 – 2020-12-31 | evidence 0001715768-21-000035 |
| FY 2019 | $-11.9M | 2019-01-01 – 2019-12-31 | evidence 0001715768-21-000035 |
| FY 2018 | $-42.1k | 2017-07-01 – 2018-06-30 | evidence 0001213900-18-013174 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).